📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-03 11:56
709 analysed today
709
Today
133,598
All-time analysed
40,124
Positive
6,284
Negative
79,370
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
24 announcements match the current filters (relevance ≥ 5).
Suven Completes Phase-3 Patient Enrollment (424 Patients) for Lead Alzheimer's Asset SUVN-502
Suven Life Sciences has completed patient enrollment in its global Phase-3 clinical study of lead asset Masupirdine (SUVN-502) for Agitation associated with Alzheimer's Dementia (AAD). A total of 424 patients were randomized across sites in the USA and Europe, exceeding the original target of 375 patients. The last patient last visit is projected by end of December 2026, with database lock by March 2027 and topline clinical results expected by May 2027. As a pure-play clinical biopharma firm with TTM revenues of Rs 9 Cr and net losses of Rs 241 Cr, SUVN-502 is the company's primary value driver.
Confidence: HIGH
What changedSuccessfully closed enrollment for the pivotal global Phase-3 clinical trial of lead candidate Masupirdine (SUVN-502) ahead of original sample size.
Why it mattersSuven's valuation rests almost entirely on clinical success and subsequent commercialization/out-licensing of SUVN-502; completing enrollment establishes a definitive timeline toward May 2027 data readout.
Patients randomized: 424Planned patient target: 375Last patient last visit target: December 2026Topline results expected: May 2027
📅 Short termProvides positive operational sentiment by meeting study recruitment milestones without safety flags observed to date.
📈 Long termThe binary outcome of the May 2027 Phase-3 readout will determine whether Suven can commercialize or license a major CNS therapy, fundamentally deciding its long-term financial viability.
⚠ Risk flags
- High binary clinical trial risk inherent to Phase-3 CNS/Alzheimer's programs
- Substantial ongoing cash burn with TTM net losses of Rs 241 Cr against Rs 9 Cr TTM revenue
Key Highlights
Randomized 424 patients across USA and Europe, surpassing the planned target of 375 patients
Trial tests Masupirdine (50 mg, 100 mg, vs placebo) once daily over 12 weeks for Alzheimer's agitation
Last patient last visit (LPLV) anticipated by end of December 2026
Database lock targeted for end of March 2027, with topline trial results expected by May 2027
👀 What to Watch
Track the completion of patient visits by December 2026 and the crucial readout of topline Phase-3 efficacy data expected in May 2027.
₹127.6 Cr Net Loss: Suven Life Sciences Q1 FY27 Results Show Surging R&D Spend
Suven Life Sciences reported a consolidated net loss of ₹127.61 Cr for Q1 FY27, a sharp increase from the ₹45.60 Cr loss in the previous quarter. This widening loss is primarily driven by a nearly 3x surge in R&D expenses, which reached ₹123.83 Cr as clinical trial activities likely intensified. While revenue from operations grew to ₹3.57 Cr from ₹1.52 Cr sequentially, the company remains in a high-burn phase typical of NCE-focused biotechs. The company is currently utilizing proceeds from a ₹857.64 Cr warrant issue to fund operations, with ₹448.14 Cr remaining as of June 30, 2026.
Confidence: HIGH
What changedQuarterly net losses nearly tripled sequentially due to a massive increase in R&D expenditure for clinical trials.
Why it mattersAs a pre-revenue biopharma firm, Suven's survival and growth depend entirely on its ability to fund and successfully complete clinical trials for its neurodegenerative disorder treatments.
Consolidated Net Loss: ₹127.61 CrR&D Expenses: ₹123.83 CrRevenue from Operations: ₹3.57 CrUnutilized Fundraise: ₹448.14 CrR&D vs Total Expenses: 89.3%
📅 Short termThe stock may face negative pressure due to the significant widening of losses and high cash burn reported this quarter.
📈 Long termThe long-term outlook is binary, depending on the successful out-licensing or commercialization of its lead NCE candidates like SUVN-502.
⚠ Risk flags
- High cash burn rate
- Total dependence on clinical trial outcomes
- Minimal operating revenue
Key Highlights
Consolidated net loss widened to ₹127.61 Cr in Q1 FY27 compared to ₹45.60 Cr in Q4 FY26
R&D expenses surged to ₹123.83 Cr, representing 89.3% of total consolidated expenses
Revenue from operations stood at ₹3.57 Cr, a 135% increase from the previous quarter's ₹1.52 Cr
The company has a remaining balance of ₹448.14 Cr from preferential issue proceeds of ₹857.64 Cr
Employee benefit expenses included ₹1.46 Cr related to ESOPs granted during the quarter
👀 What to Watch
Monitor the progress of SUVN-502 clinical trials and the burn rate of the remaining ₹448 Cr cash balance, as the company's valuation is tied to NCE commercialization success.
Suven Life Sciences AGM: $1M Max Salary for RPT and Fund Reallocation Proposed
Suven Life Sciences has scheduled its 37th AGM for August 25, 2026, to seek approval for several key resolutions. Most notably, the company proposes a Related Party Transaction (RPT) to appoint Dr. Madhavi Jasti (daughter of the CMD) to its US and Singapore subsidiaries with a remuneration package starting at USD 400,000 and capped at USD 1,000,000 per annum. Additionally, the company is seeking to reallocate unutilized funds from its June 2025 preferential issue. These proposals are significant given the company's current financial state, reporting a TTM net loss of ₹276 Cr on a revenue of only ₹7 Cr.
Confidence: HIGH
What changedThe company is proposing a high-value executive appointment for a promoter's relative and shifting the intended use of capital raised in a previous funding round.
Why it mattersThe proposed maximum salary (approx. ₹8.4 Cr) exceeds the company's total TTM revenue (₹7 Cr), which may raise concerns regarding cash burn and alignment with minority shareholders during a pre-revenue phase.
Max RPT Remuneration: USD 1,000,000Initial RPT Remuneration: USD 400,000Max Salary vs TTM Revenue: ~120%TTM Net Profit: ₹-276 CrTTM Revenue: ₹7 Cr
📅 Short termThe stock may see volatility as investors react to the high remuneration proposal relative to the company's current revenue and loss-making status.
📈 Long termThe company's long-term value remains tied to the clinical success of its NCEs like SUVN-502; administrative and compensation changes are secondary to R&D outcomes.
⚠ Risk flags
- Related-party transaction with high remuneration
- Reallocation of previously raised funds
- Significant cash burn relative to revenue
Key Highlights
Proposed initial remuneration of USD 400,000 per annum for Dr. Madhavi Jasti in overseas subsidiaries.
Maximum remuneration cap for the related party transaction set at USD 1,000,000 per annum.
Proposal to vary the utilization of proceeds from the preferential issue approved on June 5, 2025.
AGM scheduled for August 25, 2026, with a remote e-voting cut-off date of August 18, 2026.
Company reported a TTM operating profit margin of -3998.8% and a net loss of ₹276 Cr.
👀 What to Watch
Monitor the voting results of the AGM, specifically the approval of the high-value RPT and the reallocation of funds, to assess corporate governance and capital discipline.
Suven to Present 5 Scientific Posters on Alzheimer's Pipeline at AAIC-2026
Suven Life Sciences will present five scientific posters at the Alzheimer's Association International Conference (AAIC) 2026 in London from July 12-15. The presentations will feature updates on the Global Phase-3 study of Masupirdine for Alzheimer's-related agitation and the Phase-2 program for Usmarapride. As a pre-revenue R&D firm with a TTM loss of Rs 276 Cr and revenue of only Rs 7 Cr, these clinical updates are the primary drivers of its Rs 8,127 Cr market valuation. The company is also actively seeking strategic partnering and out-licensing opportunities for its CNS portfolio during the event.
Confidence: HIGH
What changedSuven is transitioning from internal data collection to presenting clinical progress for its lead assets on a global scientific stage.
Why it mattersFor a clinical-stage biopharma company, scientific validation and trial progress are the only ways to justify a high market cap (Rs 8,127 Cr) against negligible current revenue (Rs 7 Cr).
Scientific Posters: 5TTM Revenue: Rs 7 CrTTM Net Profit: Rs -276 CrMarket Cap: Rs 8127 CrRecent Fundraise: Rs 299.54 Cr
📅 Short termThe stock may see volatility around the conference dates (July 12-15) as investors react to any qualitative or quantitative data shared in the posters.
📈 Long termThe long-term value is entirely dependent on the successful completion of Phase-3 trials and subsequent out-licensing or commercialization of Masupirdine.
⚠ Risk flags
- High clinical trial failure risk
- Significant cash burn (TTM PAT -Rs 276 Cr)
- Concentration risk on lead asset Masupirdine
Key Highlights
Presenting 5 scientific posters covering Phase-1 to Phase-3 clinical assets at AAIC-2026
Providing updates on the Global Phase-3 Masupirdine study targeting agitation in Alzheimer's Dementia
Showcasing the Usmarapride Phase-2 clinical development program for cognitive disorders
Company maintains 5 clinical-stage assets and 7 research pipeline projects in the CNS space
Utilizing Rs 299.54 Cr raised in H1 FY26 to fund ongoing clinical trial obligations
👀 What to Watch
Monitor for any specific clinical data or efficacy signals released during the July 12-15 conference, as these will influence the probability of success for the Phase-3 Masupirdine trial.
₹248.84 Cr Fundraise and USD 100M Singapore Subsidiary Incorporation
Suven Life Sciences has successfully raised ₹248.84 Cr through the conversion of 1.85 Cr warrants by 17 non-promoter entities at ₹134 per share. This capital infusion is massive for a company with a TTM revenue of only ₹7 Cr and significant R&D losses. Additionally, the board approved incorporating a Singapore-based subsidiary, Suven Neurosciences Pte. Ltd., with a substantial investment commitment of up to USD 100 million. These funds are likely earmarked for advancing clinical trials of their neurodegenerative disorder pipeline, including SUVN-502.
Confidence: HIGH
What changedThe company has converted warrants into equity, securing ₹248.84 Cr in cash, and established a major international clinical development arm in Singapore.
Why it mattersFor a pre-revenue biopharma firm with high cash burn (₹276 Cr TTM loss), this liquidity is critical for survival and funding expensive global clinical trials that determine the company's ultimate valuation.
Fundraise Amount: ₹248.84 CrFundraise vs Net Worth: ~16.5%Singapore Investment Commitment: USD 100 MillionIssue Price per Share: ₹134TTM Revenue: ₹7 Cr
📅 Short termThe stock may react positively to the successful capital raise and the commitment to a large-scale international expansion.
📈 Long termThe company remains a high-risk, high-reward R&D play; long-term value depends entirely on the successful commercialization or out-licensing of its NCEs.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High cash burn rate
- Clinical trial failure risk
- Significant capital commitment relative to current revenue
Key Highlights
Allotment of 1,85,70,133 equity shares at ₹134 each upon warrant conversion
Total consideration of ₹248.84 Cr received from 17 non-promoter investors
Approved investment of up to USD 100 million in a new Singapore subsidiary
Paid-up equity capital increased from 26.39 Cr shares to 28.25 Cr shares
Re-appointment of Dr. Vajja Sambasiva Rao as Independent Director for a 5-year term
👀 What to Watch
Monitor the deployment of the USD 100 million in the Singapore subsidiary and the subsequent progress of Phase 2/3 clinical trials for their lead NCE, SUVN-502.
Rs 248.8 Cr fundraise via warrant conversion and $100M Singapore subsidiary plan
Suven Life Sciences has successfully raised Rs 248.84 crore by allotting 1.86 crore equity shares to 17 non-promoter entities following warrant conversions at Rs 134 per share. This capital infusion is massive compared to the company's TTM revenue of just Rs 7 crore, providing a significant R&D runway. Simultaneously, the board approved the incorporation of a wholly-owned subsidiary in Singapore, Suven Neurosciences Pte. Ltd., with a planned investment of USD 100 million (approx. Rs 835 crore). This new entity will focus on the clinical development and commercialization of therapeutics for neurological disorders.
Confidence: HIGH
What changedThe company has significantly strengthened its cash position through warrant conversions and established a global clinical development hub in Singapore.
Why it mattersFor a biopharma firm with minimal current revenue and high R&D burn, this fundraise (35x TTM revenue) is critical for survival and advancing clinical trials. The $100M Singapore commitment represents a major strategic bet on global clinical development.
Fundraise amount: Rs 248.84 CrFundraise vs TTM Revenue: 3555%Singapore Investment: USD 100.00 MnIssue Price per share: Rs 134.00Post-issue Paid-up Capital: Rs 28.26 Cr
📅 Short termThe successful capital raise and expansion plans are likely to be viewed positively by the market, providing liquidity for ongoing trials.
📈 Long termThe company is transitioning into a global clinical-stage player; long-term value depends entirely on the successful out-licensing or commercialization of its neurodegenerative disorder pipeline.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High clinical trial failure risk
- Significant capital commitment relative to current revenue
- Equity dilution from warrant conversion
Key Highlights
Allotted 1,85,70,133 equity shares at Rs 134 per share upon conversion of warrants
Total consideration received from 17 non-promoter allottees amounts to Rs 248.84 crore
Planned investment of USD 100 million in a new Singapore-based clinical development subsidiary
Paid-up equity share capital increased to 28,25,62,686 shares from 26,39,92,553 shares
Re-appointed Dr. Vajja Sambasiva Rao as Independent Director for a 5-year term starting January 2027
👀 What to Watch
Investors should monitor the deployment of the Rs 248.84 crore fundraise and the specific clinical trial milestones associated with the new USD 100 million Singapore subsidiary. The company's valuation remains highly sensitive to the success of its lead NCE candidate, SUVN-502.
₹248 Cr fundraise and $100M Singapore expansion for clinical development
Suven Life Sciences has approved the incorporation of a wholly-owned subsidiary in Singapore with a planned investment of USD 100 million (approx. ₹835 Cr) to focus on clinical development of therapeutics. Simultaneously, the company raised ₹248.84 Cr through the allotment of 1.85 crore equity shares following the conversion of warrants at ₹134 per share. The board also confirmed the re-appointment of Dr. Vajja Sambasiva Rao as an Independent Director for a second five-year term starting January 2027. These moves provide significant liquidity for a company currently reporting a TTM loss of ₹276 Cr while pursuing high-stakes Alzheimer's drug trials.
Confidence: HIGH
What changedThe company has secured ₹248 Cr in fresh equity capital and committed to a major $100M international expansion for its R&D pipeline.
Why it mattersFor a pre-revenue biopharma firm with ₹7 Cr TTM revenue and high cash burn, this capital infusion is vital to fund expensive Phase 2/3 clinical trials and global expansion.
Fundraise amount: ₹248.84 CrSingapore Investment: USD 100.00 MnWarrant Conversion Price: ₹134Investment vs Net Worth: ~55%Post-issue Paid-up Capital: ₹28.25 Cr
📅 Short termThe successful warrant conversion and large-scale investment plan are likely to be viewed positively by the market as they address liquidity concerns.
📈 Long termThe company's value remains binary, tied to the success of its NCE pipeline; the Singapore expansion suggests a more aggressive global clinical strategy.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High clinical trial failure risk
- Significant ongoing net losses (₹276 Cr TTM)
- Equity dilution from warrant conversion
Key Highlights
Allotment of 1,85,70,133 equity shares at ₹134 each, raising a total of ₹248.84 Cr
Planned investment of USD 100 million in a new Singapore-based subsidiary, Suven Neurosciences Pte. Ltd.
Paid-up equity share capital increased to 28,25,62,686 shares from 26,39,92,553 shares
Re-appointment of Dr. Vajja Sambasiva Rao as Independent Director for a 5-year term effective Jan 21, 2027
Investment in Singapore subsidiary represents approximately 55% of the company's current net worth of ₹1503 Cr
👀 What to Watch
Monitor the clinical trial milestones for lead candidate SUVN-502 and the specific deployment timeline of the $100M capital in the Singapore subsidiary.
₹248.8 Cr raised via warrant conversion; $100M Singapore subsidiary planned
Suven Life Sciences has allotted 1.85 crore equity shares to 17 non-promoter entities following the conversion of warrants at ₹134 per share, raising ₹248.84 crore. This capital injection is highly material, representing approximately 16.5% of the company's net worth and over 35x its TTM revenue of ₹7 crore. Additionally, the board approved the incorporation of a Singapore-based subsidiary, Suven Neurosciences Pte. Ltd., with a planned investment of USD 100 million. These funds are critical for a pre-revenue biopharma firm to sustain clinical trials for its neurodegenerative disorder treatments.
Confidence: HIGH
What changedThe company converted 1.85 crore warrants into equity shares, resulting in a ₹248.84 crore cash inflow and the initiation of a major global expansion via a new Singapore subsidiary.
Why it mattersFor an R&D-focused company with a TTM loss of ₹276 crore, this liquidity is essential to fund expensive Phase 2/3 clinical trials and global regulatory filings, which are the only path to future revenue.
Total Fundraise: ₹248.84 CrFundraise vs Net Worth: 16.55%Planned WOS Investment: USD 100.00 MnIssue Price: ₹134Post-issue Paid-up Capital: 28,25,62,686 shares
📅 Short termThe immediate cash infusion strengthens the balance sheet, though the market may weigh the benefit against the equity dilution and the discounted conversion price.
📈 Long termThe $100M Singapore subsidiary signals a major commitment to global clinical development; long-term value remains entirely dependent on the success of NCE trials.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High clinical trial failure risk (100% revenue impact if SUVN-502 fails)
- Equity dilution of approximately 7%
- Significant cash burn relative to current revenue
Key Highlights
Allotment of 1,85,70,133 equity shares to 17 non-promoter investors upon warrant conversion
Total cash consideration received from allottees amounts to ₹248,83,97,822
Planned investment of USD 100 million in a new Singapore-based wholly owned subsidiary
Conversion price of ₹134 per share is at a significant discount to the current market price of ₹320.8
Paid-up equity share capital increased from 26.40 crore shares to 28.26 crore shares
👀 What to Watch
Monitor the progress of clinical trials for lead candidate SUVN-502 and the specific deployment timeline of the USD 100 million in the Singapore subsidiary. Investors should note the ~7% equity dilution resulting from this conversion.
₹248.84 Cr Fundraise via Warrant Conversion and $100M Singapore Subsidiary Incorporation
Suven Life Sciences has allotted 1.85 crore equity shares to 17 non-promoter entities following the conversion of warrants at ₹134 per share, raising ₹248.84 crore. This capital injection is massive for a company with only ₹7 crore in TTM revenue, providing critical liquidity for its R&D-heavy operations. Additionally, the board approved the incorporation of a Singapore-based subsidiary, Suven Neurosciences Pte. Ltd., with a planned investment of USD 100 million. These funds are likely earmarked for advancing clinical trials of their lead NCE candidates like SUVN-502.
Confidence: HIGH
What changedThe company has converted warrants into equity, resulting in a ₹248.84 crore cash inflow and the establishment of a major international clinical development arm in Singapore.
Why it mattersFor a pre-revenue biopharma company with a TTM loss of ₹276 crore, this fundraise is vital for survival and continuing expensive Phase 2/3 clinical trials for Alzheimer's treatments.
Fundraise Amount: ₹248.84 CrFundraise vs TTM Revenue: 3555%WOS Investment: USD 100.00 MnIssue Price: ₹134Post-issue Paid-up Capital: ₹28.26 Cr
📅 Short termThe successful capital infusion and participation of 17 investors at ₹134 (vs current price of ₹320.8) are likely to be viewed positively by the market as it secures the R&D runway.
📈 Long termThe structural shift to a Singapore subsidiary for clinical development suggests a global commercialization strategy, though the business remains high-risk due to clinical trial dependency.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High cash burn rate
- Clinical trial failure risk
- Equity dilution
- Dependence on a single lead NCE (SUVN-502)
Key Highlights
Allotment of 1,85,70,133 equity shares at an issue price of ₹134 per share
Total consideration of ₹248.84 Cr received from 17 non-promoter investors
Planned investment of USD 100 million in a new Singapore-based wholly-owned subsidiary
Paid-up equity capital increased from 26.40 crore shares to 28.26 crore shares
Re-appointment of Dr. Vajja Sambasiva Rao as Independent Director for a 5-year term starting Jan 2027
👀 What to Watch
Investors should monitor the specific clinical trial milestones for SUVN-502 and the deployment timeline of the $100 million in the Singapore subsidiary.
Suven Life Sciences to Showcase CNS Portfolio at BIO 2026; 62 Partnering Meetings Scheduled
Suven Life Sciences is participating in the BIO International Convention 2026 to showcase its Central Nervous System (CNS) clinical pipeline and explore partnering or out-licensing opportunities. The company has 62 pre-scheduled meetings to discuss late-stage assets, including Masupirdine, which is 95% enrolled in a Phase-3 study with results expected in Q2-2027. Additionally, Ropanicant is slated for a Global Phase-3 study in H1-2027 following positive Phase-2b results. These strategic engagements are critical for the company's business model of co-development and monetization of clinical assets.
Key Highlights
Scheduled 62 pre-scheduled partnering meetings with global pharmaceutical and biotech companies at BIO-2026.
Masupirdine (SUVN-502) Phase-3 study for Alzheimer's agitation is 95% enrolled with topline results expected in Q2-2027.
Ropanicant (SUVN-911) Global Phase-3 study for Major Depressive Disorder is scheduled to commence in H1-2027.
Samelisant (SUVN-G3031) Phase-3 results for Narcolepsy are projected for release in Q2-2028.
Showcasing a differentiated CNS portfolio including assets for cognitive disorders and Major Depressive Disorder.
👀 What to Watch
Investors should monitor for any follow-up announcements regarding potential out-licensing deals or strategic partnerships resulting from these meetings. The stock remains a high-conviction clinical-stage play with major catalysts expected between 2027 and 2028.
Suven Life Sciences Reports Positive Phase-2b Results for Ropanicant in MDD Treatment
Suven Life Sciences announced that its drug candidate Ropanicant (SUVN-911) met the primary endpoint in a Phase-2b trial for Major Depressive Disorder (MDD). The 45 mg twice-daily dose showed a statistically significant improvement in the MADRS score with a mean difference of -3.572 versus placebo (p=0.038) at Week 6. The trial, conducted in the US with 214 patients, also showed positive results across secondary endpoints like the Sheehan Disability Scale. The company is now planning for a Global Phase-3 registrational study.
Key Highlights
Achieved primary endpoint with a -3.572 mean difference in MADRS score versus placebo (p=0.038) at Week 6.
Per-Protocol Set demonstrated a higher mean difference of -4.067 (p=0.023) against placebo.
Secondary endpoints including Sheehan Disability Scale (SDS) showed significant improvement (p=0.039).
Safety data indicated the drug was well-tolerated with no dissociation or clinically meaningful changes in vital signs.
Suven fully owns the IP for Ropanicant and is planning a Global Phase-3 registrational study.
👀 What to Watch
This is a major de-risking milestone for Suven's CNS pipeline; investors should monitor the timeline for Phase-3 commencement and potential licensing opportunities. The successful Phase-2b results significantly enhance the commercial valuation of the company's R&D assets.
Suven Life Sciences Completes Phase-1 Study for SUVN-I6107; Advances to Phase-2
Suven Life Sciences has successfully completed the First-in-Human Phase-1 clinical study for SUVN-I6107, a novel treatment for CNS disorders. The study, involving 64 healthy volunteers across Single and Multiple Ascending Dose cohorts, demonstrated a favorable safety profile with no serious adverse events or dose-limiting toxicities. Pharmacokinetic data showed dose-proportional exposure and a mean elimination half-life of 7-11 hours, supporting its advancement into Phase-2 clinical development. This marks the fifth internally discovered candidate from Suven to reach the clinical stage, strengthening its R&D pipeline.
Key Highlights
Successfully completed Phase-1 study (NCT06705088) involving 40 SAD and 24 MAD participants.
SUVN-I6107 showed no serious adverse events (SAEs) or treatment-related discontinuations during the study.
Achieved projected therapeutic exposures with a mean elimination half-life of 7 to 11 hours.
Pharmacodynamic biomarkers confirmed CNS activity, specifically increased alertness and enhanced information processing.
The asset is now advancing to Phase-2 clinical evaluation for cognitive disorders.
👀 What to Watch
Investors should view this as a positive R&D milestone that de-risks the early-stage pipeline, though they should remain focused on the progress of late-stage assets like Masupirdine (Phase-3) for near-term value realization.
Suven Life Sciences to Present Phase-3 Samelisant Study at SLEEP-2026 Annual Meeting
Suven Life Sciences is set to present three posters at the SLEEP-2026 meeting in Baltimore, USA, focusing on its clinical candidate Samelisant (SUVN-G3031). The presentations will highlight positive Phase-2 efficacy data for excessive daytime sleepiness (EDS) and the design for the upcoming global Phase-3 AWAKE Narcolepsy Study. This participation is critical for the clinical-stage biopharmaceutical company to engage with Key Opinion Leaders (KOLs) and potential global partners. Suven currently manages five clinical-stage assets, with Samelisant being a primary focus for sleep disorder treatments.
Key Highlights
Presenting 3 posters at the 40th annual SLEEP-2026 meeting in Baltimore from June 14-17, 2026.
Showcasing positive Phase-2 efficacy data for Samelisant (SUVN-G3031) in patients with narcolepsy.
Unveiling the rationale and design for the global Phase-3 AWAKE Narcolepsy Study for EDS.
Suven scientific team scheduled to meet with Phase-3 Principal Investigators and potential partnering companies.
Company maintains a portfolio of 5 clinical-stage assets and 7 research pipeline projects.
👀 What to Watch
Investors should monitor the progress of the Phase-3 AWAKE study and any potential partnership news following the SLEEP-2026 conference, as these are key catalysts for the stock. Clinical-stage biotechs like Suven carry high risk-reward profiles based on trial outcomes.
Suven Life Sciences Reports Positive Phase 3 Interim Analysis for Masupirdine; 88% Enrolled
Suven Life Sciences has received a positive safety review and interim analysis from the independent Data and Safety Monitoring Board (DSMB) for its Phase 3 study of Masupirdine in Alzheimer's Disease Agitation. The analysis, conducted at the 50% study completion mark, confirmed no safety concerns and recommended the trial continue without any modifications or sample size increases. Currently, 88% of the planned 375-patient population is enrolled, with full enrollment expected by September 2026. Top-line results for this critical clinical asset are anticipated in the second quarter of 2027.
Key Highlights
DSMB recommended continuing the Phase 3 trial without modifications after reviewing 50% of study completers.
Interim analysis confirmed sample size adequacy for the 375-patient study, requiring no adjustments.
Approximately 88% of the planned patient population has been enrolled as of June 4, 2026.
Projected timeline includes enrollment completion by Sept 2026 and top-line results in Q2-2027.
The study is a global multicenter trial across 80 sites in North America and Europe.
👀 What to Watch
Investors should view this as a significant de-risking event for Suven's lead clinical asset, though the primary catalyst remains the top-line results expected in Q2-2027. Maintain a watch on enrollment progress updates as the company approaches its September 2026 target.
Suven Life Sciences FY26 Consolidated Net Loss Widens to ₹276.3 Cr as R&D Spends Surge
Suven Life Sciences reported a significant widening of its consolidated net loss to ₹27,634.41 Lakhs for FY26, compared to a loss of ₹16,074.50 Lakhs in FY25. This was primarily driven by a massive 72% increase in R&D expenses, which reached ₹24,818.81 Lakhs. While standalone revenue grew slightly to ₹711.47 Lakhs, the company remains in a heavy investment phase for its drug discovery pipeline. Notably, the company's total equity increased significantly during the year, suggesting successful capital infusion to fund operations.
Key Highlights
Consolidated net loss widened to ₹276.34 Cr in FY26 from ₹160.75 Cr in FY25
R&D expenses surged 72.4% YoY to ₹248.19 Cr, accounting for 83% of total consolidated expenses
Consolidated total income grew 19.9% to ₹21.04 Cr from ₹17.55 Cr YoY
Equity share capital increased to ₹26.37 Cr from ₹21.81 Cr, reflecting capital raising activities
BSE has waived fines for prior non-compliance with Regulation 19, while NSE decision is pending
👀 What to Watch
Investors should focus on clinical trial progress and the drug discovery pipeline rather than short-term profitability, as the company remains in a high-spend R&D phase. Monitor the cash burn rate and any upcoming updates on patent approvals or clinical milestones.
Suven Life Sciences FY26 Consolidated Net Loss Widens to ₹276.34 Cr on Higher R&D Spend
Suven Life Sciences reported a significant widening of its consolidated net loss to ₹276.34 crore for FY26, compared to a loss of ₹160.75 crore in FY25. The primary driver for the increased loss was a 72% surge in Research & Development (R&D) expenses, which reached ₹248.19 crore. While total consolidated income grew slightly to ₹21.04 crore, the company's heavy investment in its drug discovery pipeline continues to impact the bottom line. Additionally, the company is addressing regulatory non-compliance issues, with BSE having already waived associated fines.
Key Highlights
Consolidated net loss widened to ₹27,634.41 lakhs (₹276.34 Cr) in FY26 from ₹16,074.50 lakhs in FY25.
R&D expenses surged to ₹24,818.81 lakhs in FY26, accounting for the bulk of total expenses.
Consolidated total income for the year ended March 31, 2026, stood at ₹2,104.48 lakhs compared to ₹1,755.27 lakhs in FY25.
Paid-up equity share capital increased to ₹2,637.20 lakhs from ₹2,180.74 lakhs year-on-year.
BSE waived fines for non-compliance with Regulation 19 (LODR); a waiver application is pending with NSE.
👀 What to Watch
Investors should treat Suven as a high-risk R&D-driven play where profitability is secondary to clinical trial progress and patent milestones. Monitor the cash burn rate closely as the company continues to incur heavy losses to fund its drug discovery pipeline.
Suven Life Sciences Reaches 76% Enrollment in Global Phase 3 Masupirdine Trial
Suven Life Sciences has achieved a 76% enrollment milestone in its Global Phase 3 clinical trial for Masupirdine (SUVN-502), which targets agitation in Alzheimer's Dementia. The study involves 375 patients across 80 sites in the USA and Europe, with full enrollment expected by the end of calendar year 2026. Management anticipates the last patient visit in Q1 2027, leading to a critical data readout by April 2027. This progress is a significant step for the company's lead CNS asset, potentially offering a non-sedative treatment for a high-unmet-need condition.
Key Highlights
Achieved 76% enrollment in a 375-patient Global Phase 3 study for Masupirdine (SUVN-502).
Enrollment completion is targeted for the end of 2026, with a final data readout expected by April 2027.
The trial is conducted across 80 sites in North America and Europe, utilizing a 1:1:1 randomization for 50mg, 100mg, and placebo doses.
Masupirdine acts as a selective 5-HT6 receptor antagonist, aiming to provide a non-dopaminergic approach to Alzheimer's agitation.
👀 What to Watch
Investors should closely monitor the company's progress toward the end-2026 enrollment deadline as a key de-risking milestone. The stock remains a high-conviction play on the April 2027 Phase 3 data readout, which will be a major binary catalyst for the company's valuation.
Suven Life Sciences Allots 3.17 Cr Shares to Promoters, Raising Rs 425.7 Crore
Suven Life Sciences has successfully converted 3,17,68,764 warrants into equity shares, resulting in a significant capital infusion of Rs 425.7 crore. The shares were allotted to the promoter group entity, Jasti Property and Equity Holdings Private Limited, at an issue price of Rs 134 per share. This transaction increases the company's total paid-up equity capital from 23.19 crore shares to 26.37 crore shares. The receipt of 100% consideration from the promoters demonstrates strong internal confidence in the company's long-term value.
Key Highlights
Allotment of 3,17,68,764 equity shares to the promoter group upon conversion of warrants.
Total capital infusion of Rs 425,70,14,376 received at an issue price of Rs 134 per share.
Paid-up equity share capital increased to 26,37,20,583 shares of Rs 1 each.
The allottee is Jasti Property and Equity Holdings Private Limited (Jasti Family Trust).
The board meeting for the allotment concluded within 20 minutes on March 6, 2026.
👀 What to Watch
The promoter's decision to infuse substantial capital at Rs 134 per share is a strong signal of commitment and confidence. Investors should monitor the company's utilization of these funds toward its R&D pipeline and clinical trials.
Suven Life Sciences Allots 3.17 Cr Equity Shares to Promoter; Raises Rs 425.7 Crore
Suven Life Sciences has successfully converted 3,17,68,764 warrants into equity shares, allotting them to the promoter group entity, Jasti Family Trust. The transaction was executed at an issue price of Rs. 134 per share, resulting in a total fund infusion of Rs. 425.70 crore. This capital injection has increased the company's total paid-up equity share capital to 26.37 crore shares. The 100% receipt of consideration from the promoter highlights strong internal support for the company's long-term objectives.
Key Highlights
Allotment of 3,17,68,764 equity shares at Rs. 134 per share (including Rs. 133 premium).
Total consideration received from the promoter group amounts to Rs. 425.70 crore.
The allotment was made to Jasti Property and Equity Holdings Private Limited (Jasti Family Trust).
Paid-up equity capital increased from 23,19,51,819 to 26,37,20,583 shares.
The board meeting for this allotment was concluded on March 6, 2026.
👀 What to Watch
The promoter's decision to exercise warrants at Rs. 134 suggests a bullish outlook on the company's valuation. Investors should maintain their positions while watching for updates on the utilization of these funds in clinical trials or R&D.
Suven Life Sciences Raises ₹60 Crore via Warrant Conversion; Appoints New Company Secretary
Suven Life Sciences has successfully raised ₹60 crore through the allotment of 44.77 lakh equity shares to 3P India Equity Fund entities. This allotment follows the conversion of fully paid warrants at an issue price of ₹134 per share, which is a significant premium over the face value. Consequently, the company's paid-up equity share capital has increased to 23.19 crore shares. Additionally, the company announced the appointment of Ms. Sangeetha Laxmi Kandari as the new Company Secretary and Compliance Officer, effective February 2, 2026, following the resignation of Mr. Shrenik Soni.
Key Highlights
Allotted 44,77,612 equity shares at an issue price of ₹134 per share (₹1 face value + ₹133 premium)
Total capital raised through warrant conversion amounts to ₹60,00,00,008
Post-issue paid-up equity capital increased from 22,74,74,207 to 23,19,51,819 shares
Institutional investors 3P India Equity Fund 1 and 1M were the sole allottees in this conversion
Ms. Sangeetha Laxmi Kandari appointed as CS & Compliance Officer with over 9 years of experience
👀 What to Watch
Investors should view the ₹60 crore capital infusion from institutional funds as a positive sign of confidence in the company's valuation. Monitor the company's upcoming R&D updates to see how this capital is deployed for growth.
